PDS Biotechnology
PDSB
52 hedge funds and large institutions have $6.78M invested in PDS Biotechnology in 2026 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 4 closing their positions.
275% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 4
122% more capital invested
Capital invested by funds: $3.05M → $6.78M (+$3.72M)
86% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 7
27% more funds holding
Funds holding: 41 → 52 (+11)
4.14% more ownership
Funds ownership: 9.64% → 13.78% (+4.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Focus Partners Wealth
Boston,
Massachusetts
|
+$682K |
| 2 |
QCM
Quantinno Capital Management
New York
|
+$682K |
| 3 |
MCM
Militia Capital Management
Austin,
Texas
|
+$352K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$344K |
| 5 |
Morgan Stanley
New York
|
+$329K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$105K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$77.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$47.6K |
| 4 |
NMC
Nine Masts Capital
Central,
Hong Kong
|
-$40.8K |
| 5 |
WG
Wealth Group
Raleigh,
North Carolina
|
-$8K |
PDSB Hedge Fund Activity: Q2 2026 in Review
52 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q2 2026, worth a combined $6.78M — up 122% from $3.05M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new PDSB positions and 4 closed out — a net gain of 11 holders — while 13 added to existing stakes and 7 trimmed.
The largest buyer was Focus Partners Wealth, opening a new position worth an estimated $682K. The largest seller was Armistice Capital, exiting entirely with an estimated $105K sold.
- 52 institutional investors held PDS Biotechnology (PDSB) as of Q2 2026, up from 41 in Q1 2026.
- Funds reported $6.78M of PDS Biotechnology stock for Q2 2026, up 122% quarter-over-quarter.
- 15 funds opened new PDS Biotechnology positions in Q2 2026 and 4 closed out, a net change of +11 holders.
- The largest PDS Biotechnology buyer in Q2 2026 was Focus Partners Wealth, an estimated $682K added.
- The largest PDS Biotechnology seller in Q2 2026 was Armistice Capital, an estimated $105K sold.
Based on aggregated 13F filings for Q2 2026.